Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from D.Western Therapeutics Institute ( (JP:4576) ) is now available.
D. Western Therapeutics Institute announced that its partner Kowa has begun sales in Singapore of GLA-ALPHA Combination Ophthalmic Solution, a fixed-dose eye drop that combines the company’s in-house discovered Rho-kinase inhibitor ripasudil hydrochloride hydrate with brimonidine tartrate for the treatment of glaucoma and ocular hypertension. The product, already launched in Japan, Thailand and Malaysia, offers a novel mechanism versus existing combination therapies, is expected to support better intraocular pressure control and adherence for patients using multiple eye medications, and will generate royalty income for DWTI, with the financial impact to be incorporated into its earnings forecast for the year ending December 2026.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
More about D.Western Therapeutics Institute
D. Western Therapeutics Institute, Inc. is a Japan-based biopharmaceutical company focused on discovering and developing ophthalmic drugs, including innovative treatments for glaucoma and ocular hypertension. The company advances its compounds primarily through out-licensing arrangements with partners such as Kowa Co., Ltd., leveraging collaborators for commercialization and overseas market expansion.
Average Trading Volume: 694,603
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.37B
See more insights into 4576 stock on TipRanks’ Stock Analysis page.